MedTrace Logo

Influence of Fluvoxamine on the Pharmacokinetics of BI 409306

NCT02853136 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-08-21

Study results available
· View outcomes & findings →

Summary

To investigate the influence of fluvoxamine on the pharmacokinetics of BI 409306

Conditions

  • Healthy

Interventions

DRUG

Fluvoxamine

Fluvoxamine

DRUG

BI 409306 - Powder for oral solution (PfOS)

BI 409306 - Powder for oral solution (PfOS)

DRUG

BI 409306 - film coated tablet

BI 409306 - film coated tablet

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-25
Primary Completion
2016-10-17
Completion
2016-10-25

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02853136 on ClinicalTrials.gov